

VIA FACSIMILE  
USSN 09/662,783

### AMENDMENTS TO THE CLAIMS

Amend the claims as follows:

1. (Currently amended): An isolated polypeptide ~~comprising~~ consisting of the an amino acid sequence of SEQ ID NO:4, wherein said polypeptide has a growth factor activity characterized by induction of proliferation of fibroblast cells.

2. (Currently amended): ~~The polypeptide of claim 1, wherein said~~ An isolated polypeptide ~~is a fragment~~ selected from the group consisting of amino acid residues 247-370 of SEQ ID NO:2, amino acid residues 247-338 of SEQ ID NO:2, and amino acid residues 339-370 of SEQ ID NO:2, wherein the polypeptide has a growth factor activity characterized by induction of proliferation of fibroblast cells.

3 – 39. (Cancelled)

40. (Original): A pharmaceutical composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable carrier.

C  
41 – 65. (Cancelled)

66. (Currently Amended): A An isolated polypeptide dimer comprising two associated peptide fragments, wherein said peptide fragments are selected from the group consisting of amino acid residues 247-370 of SEQ ID NO:2, amino acid residues 247-338 of SEQ ID NO:2, and amino acid residues 339-370 of SEQ ID NO:2 wherein the polypeptide has a growth factor activity characterized by induction of proliferation of fibroblast cells.

67. (New): A pharmaceutical composition comprising a polypeptide of claim 2 and a pharmaceutically acceptable carrier.

68. (New): A pharmaceutical composition comprising a polypeptide of claim 66 and a pharmaceutically acceptable carrier.